https://www.globenewswire.com/news-release/2020/08/11/2076697/0/en/AzurRx-BioPharma-Announces-Positive-Interim-Data-From-First-Patient-Cohort-in-Phase-2-Clinical-Trial-of-MS1819-in-Combination-with-PERT-Therapy-in-the-Treatment-of-Cystic-Fibrosis-.html
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
